Literature DB >> 6166278

Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.

A Billiau, H Heremans, D Ververken, J van Damme, H Carton, P de Somer.   

Abstract

Preparations of human leukocyte (alpha) and fibroblast (beta) interferon were given intramuscularly to rabbits and monkeys, and circulating interferon was measured. In rabbits, but not in monkeys, a marked difference between the two interferons was noted in that higher titers of circulating antiviral activity were obtained with leukocyte than with fibroblast interferon. In mice, injected interperitoneally, a similar difference could be noted. However, levels of antiviral activity in homogenates of spleens and lungs did not differ between mice injected with either interferon. Fibroblast interferon that was injected intrathecally in monkeys was found to diffuse throughout the cerebrospinal canal and to reach the serum compartment. Some interferon could also be recovered from the pia mater surrounding the brain hemispheres, but none was found in the deeper layers of the brain.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166278     DOI: 10.1007/BF01315163

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

1.  Interferon crosses blood-cerebrospinal fluid barrier in monkeys.

Authors:  D V Habif; R Lipton; K Cantell
Journal:  Proc Soc Exp Biol Med       Date:  1975-05

2.  Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy.

Authors:  H Heremans; A Billiau; P De Somer
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

3.  Non-appearance of injected fibroblast interferon in circulation.

Authors:  V G Edy; A Billiau; P De Somer
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

4.  Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.

Authors:  J Vilcek; I T Sulea; I L Zerebeckyj; Y K Yip
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

5.  Human fibroblast interferon for clinical trials: production, partial purification, and characterization.

Authors:  A Billiau; J V Damme; F V Leuven; V G Edy; M De Ley; J J Cassiman; H Van de Berghe; P De Somer
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

6.  Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

Authors:  A Billiau; P De Somers; V G Edy; E De Clercq; H Heremans
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

  6 in total
  17 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

2.  Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

Authors:  E Villa; P Trande; A Grottola; P Buttafoco; A M Rebecchi; T Stroffolini; F Callea; A Merighi; L Camellini; P Zoboli; R Cosenza; L Miglioli; P Loria; R Iori; N Carulli; F Manenti
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 3.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 4.  The interferon system as a basis for antiviral therapy or prophylaxis.

Authors:  A Billiau
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

5.  The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.

Authors:  V Bocci; M Muscettola; G Grasso; Z Magyar; A Naldini; G Szabo
Journal:  Experientia       Date:  1986-04-15

Review 6.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

7.  Behavioral evaluation of transgenic mice with CNS expression of IFN-alpha by elevated plus-maze and Porsolt swim test.

Authors:  Hua Zhang; Zhanzhuang Tian; Jianping Wang
Journal:  Neurosci Lett       Date:  2010-06-04       Impact factor: 3.046

8.  Pharmacokinetics of an extended-release human interferon alpha-2b formulation.

Authors:  A Bonetti; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Distribution of mouse interferon-beta in normal and brain tumour-bearing mice.

Authors:  Y Mihara; J Kuratsu; S Takaki; K Hori; E Nagai; Y Satoh; N Minowa; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

10.  Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice.

Authors:  L Ozzello; D V Habif; C M DeRosa
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.